

**ARRANGEMENTS OF PAYMENT FOR PRODUCTS SUPPLIED FREE OF CHARGE OR
PRODUCTS WITH A NOMINAL PRICE (ENGLAND)**

The price listed in respect of a drug specified in the following list is the basic price (see Part II, Clause 8) on which payment will be calculated pursuant to Part I Clause 5B.1 for the dispensing of that drug.

The products listed in this Part are products -

- (i) that the Secretary of State has centrally secured and has made arrangements for the product to be supplied to pharmacy contractors, whether directly or via an intermediary, at no cost to the pharmacy contractor, or
- (ii) the Secretary of State is on notice are available from a manufacturer or supplier at a nominal price that is significantly below the NHS list price for the product because of a commercial arrangement between NHS England and the manufacturer or supplier of the product. In these circumstances, reimbursing pharmacy contractors at the NHS list price (which would ordinarily be reflected in the Category C price) would not represent value for money. Accordingly, the Secretary of State determines a basic price for products in this Part that is based on the nominal price of the listed pack size, and so takes account of the commercial arrangement between NHS England and the manufacturer or supplier, although the Secretary of State will not have been privy to the detail of the commercial arrangement.

Where contractors are unable to source the products listed at or below the basic price listed in this Part, or who are subjected to additional charges when purchasing the products listed in this Part, they may request a review of the basic price and repayment of any additional costs incurred. The review requires the following steps to be taken. If there are any issues with the supply, ordering and pricing of the product, contractors must first contact the suppliers of the product for notification and resolution. Should no resolution be identified by the suppliers within 5 working days of receipt, then contractors should escalate to Community Pharmacy England. To support the handling of the review, contractors are required to submit evidence of any difficulties experienced including issues with pricing or supply. Any claims and supporting evidence will then be referred by Community Pharmacy England to the Department of Health and Social Care. Following a successful review, where pricing issues are identified, any adjustments will be applied by the Pricing Authority to the contractors account at the earliest possible payment date

PRODUCTS UNDER PART VIIC(i)

For May 2025, for electronic and non-electronic prescription forms, where a contractor dispenses centrally procured stock of Nirmatrelvir 150mg tablets and Ritonavir 100mg tablets (Paxlovid 150mg/100mg tablets), the contractor must select the "NCSO" endorsement. Where the contractor endorses "NCSO", the Pricing Authority will reimburse as per Part VIIC (i) of the Drug Tariff.

Where the contractor has purchased commercially available stock of Nirmatrelvir 150mg tablets and Ritonavir 100mg tablets (Paxlovid 150mg/100mg tablets), no endorsement should be made and the Pricing Authority will reimburse as per Clause 8C, Part II of the Drug Tariff.

Drug	Quantity	Basic Price (p)
Nirmatrelvir 150mg tablets and Ritonavir 100mg tablets	30	250
Paxlovid 150mg/100mg tablets	30	250

PRODUCTS UNDER PART VIIC(ii)

Drug	Quantity	Basic Price (p)
Inclisiran 284mg/1.5ml solution for injection pre-filled syringes	1	6000
Leqvio 284mg/1.5ml solution for injection pre-filled syringes	1	6000